C-RAD

C-RAD continues to advance its capabilities in proton therapy, having recently validated two additional Particle Therapy Systems for respiratory gating with Catalyst+ PT. These achievements bolster their position as a leader in this high-precision treatment modality, further solidifying its role as a trusted partner for healthcare providers around the world.

C-RAD is continuing their collaborative journey with RaySearch Laboratories AB (publ), aiming to jointly develop innovative solutions and products to enhance the quality of radiation therapy, building on the foundation announced at ESTRO this year.

As part of this ongoing collaboration, experts from both teams will showcase recent developments and exciting new clinical scenarios at the RaySearch and C-RAD booths.

In line with its strong partnership with Accuray, C-RAD will highlight Catalyst+ HD at Accuray’s Exchange Academy, a key feature of Accuray’s program at ASTRO. This collaboration underscores the integration of C-RAD’s advanced technologies with Accuray’s systems, showcasing the latest innovations and clinical benefits aimed at improving patient outcomes in radiation therapy.

“We are thrilled to present our most extensive SGRT interoperability portfolio at ASTRO 2024, including VitalHold™ for Accuray Radixact®, and to demonstrate our commitment to pushing the boundaries of SGRT,” said Cecilia de Leeuw, President and CEO of C-RAD. “We are excited about the future of our partnerships as we continue to innovate and drive advancements in cancer treatment.”

C-RAD will also participate in the ASRT Radiation Therapy Conference, in conjunction with ASTRO, to engage with radiation therapy professionals on the latest in SGRT technologies.